• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

NICE consulting on possible new indicators for stroke
Source: PharmacoEconomics and Outcomes News - February 1, 2016 Category: Drugs & Pharmacology Source Type: news

NICE recommends Xarelto® as a treatment option for reducing secondary events in ACS
The National Institute for Health and Care Excellence (NICE) issued its Final Appraisal Determination (FAD) recommending Xarelto 2.5mg twice daily as an effective treatment option for preventing secondary events – such as death, heart attack or stroke – following acute coronary syndrome (ACS) in patients with elevated cardiac biomarkers, without prior stroke or transient ischaemic attack (TIA). (1) The FAD is the final phase in a multi-step review process by NICE and recognises the improved patient outcomes using Xarelto as a treatment option on top of dual antiplatelet therapy;* publication of guidance is expected to follow in Q1 2015.
Source: Pharmacy Europe - January 27, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Cost effectiveness Industry News Cardiovascular medicine Legislation & regulation Patient care acs antiplatelet therapy ATLAS ACS 2 TIMI 51 Latest News TIA Xaltero Source Type: news

RPS responds to NICE Guideline on Atrial Fibrillation
Responding to new guidance from NICE on how best to treat people at serious risk of a stroke because of an abnormal heart rhythm, known as atrial fibrillation (AF), Helen Williams, Consultant Pharmacist and RPS spokesperson on ca
Source: Royal Pharmaceutical Society News - June 17, 2014 Category: Drugs & Pharmacology Source Type: news

NICE Final Appraisal Determination on ELIQUIS®
Bristol-Myers Squibb and Pfizer Ltd. have announced that the National Institute for Health and Clinical Excellence (NICE) has issued a fast-tracked Final Appraisal Determination (FAD) recommending the oral anticoagulant Eliquis (apixaban) as an option for preventing stroke and systemic embolism, in patients with non-valvular atrial fibrillation (AF) with one or more risk factors.
Source: Pharmacy Europe - January 24, 2013 Category: Drugs & Pharmacology Source Type: news

NICE consults on potential new QOF indicators for 2014/15
Source: NICE Area: News NICE is inviting comment from stakeholders on 14 potential new indicators for consideration for the 2014/15 Quality and Outcomes Framework (QOF), covering the following topics:   . Hypertension . Dementia . Coronary heart disease . Diabetes (including tightly linked measures) . Peripheral arterial disease . Stroke and TIA   The consultation will close at 5pm on 4th February 2013.
Source: NeLM - News - January 7, 2013 Category: Drugs & Pharmacology Source Type: news